Fecal calprotectin as a predictor of abnormal colonic histology

Diseases of the Colon and Rectum

Volumn 50, Issue 12, 2007, Pages 2188-2193

  Shitrit, Ariella Bar Gil ^a   Braverman, Dan ^a   Stankiewics, Halina ^a   Shitrit, David ^b,c   Peled, Nir ^b,c   Paz, Kalman ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Calprotectin; Colon; Colonoscopy; Pathology

Indexed keywords

CALGRANULIN;

ARTICLE; BLOOD ANALYSIS; BLOOD EXAMINATION; CLINICAL ARTICLE; COLON MALFORMATION; COLONOSCOPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; MULTIVARIATE ANALYSIS; OCCULT BLOOD; RECEIVER OPERATING CHARACTERISTIC;

BIOLOGICAL MARKERS; COLONIC DISEASES; COLONOSCOPY; CONFIDENCE INTERVALS; DIAGNOSIS, DIFFERENTIAL; FECES; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; PROGNOSIS; PROSPECTIVE STUDIES; ROC CURVE;

EID: 37249010692     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1007/s10350-007-9038-x     Document Type: Article

References (15)

1. Hoff G, Grotmol T, Thilis-Evensen E, et al. Testing for fecal calprotectin in the Norwegian colorectal cancer prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood. Gut 2004;53:1329-33.
2. Ton H, Brandness Q, Holtlund J, et al. Improved assay for fecal calprotectin. Clin Chim Acta 2000;292:41-54.
3. Kronborg O, Ustad M, Fuglerud P, et al. Fecal calprotectin levels in a high risk population for colorectal neoplasia. Gut 2000;46:795-800.
4. Limburg PJ, Devens ME, Harrington JJ, et al. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia. Am J Gastroenterol 2003;98:2299-305.
5. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22.
6. Costa F, Mumolo MG, Bellini M, et al. Role of faecal calprotectin as a non-invasive marker of intestinal inflammation. Dig Liver Dis 2003;35:642-7.
7. Fagerhol MK. Calprotectin. A faecal marker of organic gastrointestinal abnormality. Lancet 2000;356:1783-4.
8. Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991;32:174-8.
9. Modigliani R. Endoscopic management of inflammatory bowel disease. Am J Gastroenterol 1994;89:53-65.
10. Kristinsson J, Roseth A, Fagerhol MK, et al. Fecal calprotectin concentration in patients with colorectal carcinoma. Dis Colon Rectum 1998;41:316-21.
11. Gilbert JA, Ahlquist DA, Mahoney DW, et al. Fecal marker variability in colorectal cancer: calprotectin versus hemoglobin. Scand J Gastroenterol 1996;31:1001-5.
12. Dale IB, Fagerhol MK, Scott H. Distribution of a new myelomonocytic antigen (L-1) in human peripheral blood leukocytes. Am J Clin Pathol 1985;84:24-34.
13. Fagerhol MK, Dale I, Anderson I. Release and quantitation of a leucocyte derived protein (L1). Scand J Haematol 1980;24:393-8.
14. Roseth AG, Kristinsson J, Fagerhol MK, et al. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 1993;28:1073-6.
15. Tibble J, Sigthorsson G, Foster R, et al. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001;49:402-8.